Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company…
Month: August 2023
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy,…
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy,…
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
SCYNEXIS to Participate in September Investor Conferences
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
SCYNEXIS to Participate in September Investor Conferences
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
Rhythm Pharmaceuticals to Present at Investor Conferences in September
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Rhythm Pharmaceuticals to Present at Investor Conferences in September
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders
New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from…
BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders
New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from…
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company…
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company…
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions…
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions…
Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling…